HERCULES, CA -- (Marketwired) -- 06/23/14 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), today announced the launch of the BioPlex® 2200 25-OH Vitamin D kit for use outside the U.S. on the company's BioPlex® 2200 system. The assay offers a fully-automated method for the quantitative measurement of total 25-hydroxyvitamin D in human serum.
The Vitamin D testing market has seen considerable growth over the past several years. In addition to the critical role Vitamin D plays in bone health, a number of recent studies have demonstrated associations between Vitamin D deficiency and an increased risk of cardiovascular disease, autoimmune disease, and cancer. Physicians have increasingly begun to include Vitamin D testing as part of the routine assessment of a patient's overall health.
"We are pleased to offer the BioPlex 2200 25-OH Vitamin D kit to address this important area of testing," said John Goetz, Bio-Rad Executive Vice President and President, Clinical Diagnostics Group. "The Vitamin D kit expands our already extensive menu of autoimmune and infectious disease assays and offers our customers another option to streamline their testing."
The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system and provides clinical laboratories with the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately. The BioPlex 2200 system conserves patient sample volume, helps consolidate workstations, and simplifies workflow.
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) designs, manufactures, and distributes a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs over 7,750 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.